Teva sets out euro stall as dollars crunch tighter
With its $15bn of new bonds ratcheting tighter, Israeli-American pharmaceutical company Teva has set out the structure of the euro part of its M&A bond financing for the acquisition of Allergan's generic drugs business.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: